Newron Pharmaceuticals S.p.A. (0QOI.L)
CHF 8.22
(0.24%)
CHF 8.22
(0.24%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.91 EUR | 7.14% |
| 2022 | -0.98 EUR | -16.67% |
| 2021 | -0.84 EUR | 28.81% |
| 2020 | -1.18 EUR | -4.42% |
| 2019 | -1.13 EUR | -34.52% |
| 2018 | -0.84 EUR | -162.5% |
| 2017 | -0.32 EUR | 69.23% |
| 2016 | -1.04 EUR | 37.35% |
| 2015 | -1.66 EUR | -107.5% |
| 2014 | -0.80 EUR | -29.03% |
| 2013 | -0.62 EUR | -113.79% |
| 2012 | -0.29 EUR | 67.42% |
| 2011 | -0.89 EUR | 71.38% |
| 2010 | -3.11 EUR | 19.43% |
| 2009 | -3.86 EUR | -40.88% |
| 2008 | -2.74 EUR | -44.21% |
| 2007 | -1.90 EUR | 56.12% |
| 2006 | -4.33 EUR | 18.15% |
| 2005 | -5.29 EUR | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -0.51 EUR | 0.0% |
| 2023 Q2 | -0.39 EUR | 0.0% |
| 2023 FY | - EUR | 7.14% |
| 2023 Q4 | -0.52 EUR | 0.0% |
| 2022 FY | - EUR | -16.67% |
| 2022 Q2 | -0.48 EUR | 0.0% |
| 2022 Q4 | -0.50 EUR | 0.0% |
| 2021 Q2 | -0.51 EUR | 0.0% |
| 2021 Q4 | -0.33 EUR | 0.0% |
| 2021 FY | - EUR | 28.81% |
| 2020 FY | - EUR | -4.42% |
| 2020 Q4 | -0.59 EUR | 0.0% |
| 2020 Q2 | -0.59 EUR | 0.0% |
| 2019 Q4 | -0.35 EUR | 0.0% |
| 2019 FY | - EUR | -34.52% |
| 2019 Q2 | -0.79 EUR | 0.0% |
| 2018 Q2 | -0.42 EUR | 0.0% |
| 2018 Q4 | -0.42 EUR | 0.0% |
| 2018 FY | - EUR | -162.5% |
| 2017 Q2 | 0.09 EUR | 0.0% |
| 2017 FY | - EUR | 69.23% |
| 2017 Q4 | -0.41 EUR | 0.0% |
| 2016 Q2 | -0.64 EUR | 0.0% |
| 2016 FY | - EUR | 37.35% |
| 2016 Q4 | -0.41 EUR | 0.0% |
| 2015 FY | - EUR | -107.5% |
| 2015 Q2 | -0.52 EUR | 0.0% |
| 2015 Q4 | -1.13 EUR | 0.0% |
| 2014 Q4 | -0.42 EUR | 0.0% |
| 2014 FY | - EUR | -29.03% |
| 2014 Q2 | -0.37 EUR | 0.0% |
| 2013 Q4 | -0.40 EUR | -166.67% |
| 2013 FY | - EUR | -113.79% |
| 2013 Q3 | -0.15 EUR | 28.57% |
| 2013 Q2 | -0.21 EUR | 0.0% |
| 2012 Q1 | -0.07 EUR | 0.0% |
| 2012 Q2 | -0.07 EUR | 0.0% |
| 2012 FY | - EUR | 67.42% |
| 2012 Q3 | -0.07 EUR | 0.0% |
| 2012 Q4 | -0.15 EUR | -106.04% |
| 2011 Q3 | -0.22 EUR | 0.0% |
| 2011 Q1 | -0.22 EUR | 0.0% |
| 2011 Q2 | -0.22 EUR | 0.0% |
| 2011 FY | - EUR | 71.38% |
| 2011 Q4 | -0.07 EUR | 66.91% |
| 2010 Q3 | -0.78 EUR | 0.0% |
| 2010 FY | - EUR | 19.43% |
| 2010 Q1 | -0.78 EUR | 0.0% |
| 2010 Q4 | -0.22 EUR | 71.79% |
| 2010 Q2 | -0.78 EUR | 0.0% |
| 2009 Q4 | -0.78 EUR | 18.75% |
| 2009 FY | - EUR | -40.88% |
| 2009 Q3 | -0.96 EUR | 0.0% |
| 2009 Q2 | -0.96 EUR | 0.0% |
| 2009 Q1 | -0.96 EUR | 0.0% |
| 2008 Q2 | -0.69 EUR | 0.0% |
| 2008 Q1 | -0.69 EUR | 0.0% |
| 2008 FY | - EUR | -44.21% |
| 2008 Q4 | -0.96 EUR | -39.13% |
| 2008 Q3 | -0.69 EUR | 0.0% |
| 2007 Q3 | -0.48 EUR | 0.0% |
| 2007 Q2 | -0.48 EUR | 0.0% |
| 2007 Q1 | -0.48 EUR | 0.0% |
| 2007 FY | - EUR | 56.12% |
| 2007 Q4 | -0.69 EUR | -43.75% |
| 2006 FY | - EUR | 18.15% |
| 2006 Q1 | -1.06 EUR | 0.0% |
| 2006 Q3 | -1.06 EUR | 0.0% |
| 2006 Q2 | -1.06 EUR | 0.0% |
| 2006 Q4 | -0.48 EUR | 54.72% |
| 2005 Q3 | -1.31 EUR | 0.0% |
| 2005 Q1 | -1.31 EUR | 0.0% |
| 2005 Q2 | -1.31 EUR | 0.0% |
| 2005 FY | - EUR | 0.0% |
| 2005 Q4 | -1.06 EUR | 19.08% |
| 2004 Q4 | -1.31 EUR | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Relief Therapeutics Holding AG | -8.35 CHF | 89.102% |
| Tecan Group AG | 10.34 CHF | 108.801% |
| Santhera Pharmaceuticals Holding AG | 5.18 CHF | 117.568% |
| Basilea Pharmaceutica AG | 0.87 CHF | 204.598% |
| Bachem Holding AG | 1.50 CHF | 160.667% |
| Siegfried Holding AG | 26.61 CHF | 103.42% |
| Molecular Partners AG | -1.89 CHF | 51.852% |